Pomalidomide-dipiperazine-NH2 hydrochloride

Background Introduction

Pomalidomide-dipiperazine-NH2 hydrochloride is an advanced E3 ligase ligand-linker conjugate designed for targeted protein degradation applications, particularly in Proteolysis Targeting Chimeras (PROTACs). Building on the structure of pomalidomide, a well-known immunomodulatory agent and cereblon (CRBN) E3 ligase recruiter, this product integrates a dipiperazine linker with an amino functionality, providing a versatile platform for the rational design of efficient PROTAC molecules.

Mechanism

The mechanism of Pomalidomide-dipiperazine-NH2 hydrochloride centers on its ability to engage the cereblon (CRBN) E3 ubiquitin ligase complex via the pomalidomide moiety. The dipiperazine linker functions as a flexible and hydrophilic spacer, optimizing the spatial orientation between the E3 ligase and a target protein ligand when forming a bifunctional PROTAC. The terminal amine group enables straightforward conjugation to various target-binding molecules. Upon successful recruitment of both CRBN and the protein of interest, the resulting ternary complex facilitates the ubiquitination and subsequent proteasomal degradation of the target protein, offering selective and catalytic protein knockdown.

Applications

Pomalidomide-dipiperazine-NH2 hydrochloride is widely utilized in medicinal chemistry and early-stage drug discovery for the modular assembly of PROTACs and related heterobifunctional degraders. Its superior physicochemical properties make it ideal for synthesizing PROTAC molecules targeting disease-relevant proteins in oncology, neurology, and immunology. Academic and pharmaceutical researchers employ this reagent to probe protein function, validate new therapeutic targets, and accelerate the development of next-generation targeted protein degradation therapies. The availability of a hydrochloride salt form enhances its solubility and stability, facilitating efficient chemical synthesis and biological characterization in laboratory settings.

Pomalidomide-dipiperazine-NH2 hydrochloride is an advanced E3 Ligase Ligand-Linker Conjugate designed for the development of PROTACs, facilitating targeted protein degradation by linking an E3 ligase ligand with a target protein ligand. This molecule's structure is optimized for efficient degradation pathways, providing researchers with a robust tool for studying protein function and regulation.

Linker: The linker in this molecule is a dipiperazine moiety, offering moderate flexibility and a balanced length that ensures optimal spatial arrangement between the ligand and the target protein. Its non-cleavable nature provides stability, making it suitable for sustained interactions in cellular environments.

Ligand: The ligand component is based on pomalidomide, a derivative of thalidomide, known for its high affinity to cereblon, an E3 ubiquitin ligase. Its structural characteristics include a glutarimide ring, which is crucial for binding efficacy and selectivity in targeted protein degradation applications.

Reactive Site: The reactive site features an amino group (NH2) that efficiently couples with electrophilic groups on the target protein ligand. Recommended reaction types include amide bond formation or nucleophilic substitution, facilitating robust and stable conjugation necessary for effective PROTAC function.

Recommended Target Protein Ligand: An ideal warhead for this molecule would be a small-molecule inhibitor or modulator with an electrophilic functional group, such as a carbonyl or sulfonyl chloride. This compatibility enhances the specificity and efficacy of the PROTAC, enabling precise degradation of proteins implicated in disease pathways, thus advancing experimental research in cellular and molecular biology.